Want to see AU:CU6 full AI Analyst Report?

Clarity Pharmaceuticals Ltd. (CU6) Price & Analysis

300 Followers

CU6 Stock Chart & Stats

AU$2.50

-AU$0.09(-4.04%)

At close: Jul 28 4:00 PM EDT

AU$2.50

-AU$0.09(-4.04%)

Day’s Range― - ―

52-Week RangeAU$1.69 - AU$5.14

Previous CloseN/A

Volume1.02M

Average Volume (3M)2.11M

Market Cap

AU$660.35M

Enterprise ValueAU$619.33M

Total Cash (Recent Filing)AU$178.25M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta2.42

Next Earnings

Mar 04, 2027

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding373,081,240

10 Day Avg. Volume2,898,433

30 Day Avg. Volume2,112,506

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)4.23

Price to Sales (P/S)0.00

P/FCF Ratio-8.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$6.79

Price Target Upside171.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.32

Revenue Forecast (FY)AU$7.93M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe absence of reported debt reduces solvency and refinancing pressure while preserving financial flexibility. A debt-free structure gives Clarity more room to fund clinical development and manage volatility without mandatory interest or principal payments competing with research spending.

Growing Equity BasePositive and expanding equity provides support for the company’s asset base and indicates that its funding structure remains substantial despite ongoing losses. This capital cushion can help sustain development programs and preserve strategic flexibility over the next several quarters.

Prior Revenue And Gross-profit TractionThe strong revenue expansion achieved through 2024 and historically high gross margins show that Clarity has previously generated meaningful commercial or development-related top-line activity. If revenue generation resumes, that history suggests potential operating leverage from a high-margin product model.

Bears Say

Revenue DisruptionA decline followed by zero reported revenue represents a severe disruption to top-line generation and weakens visibility into the company’s near-term economic model. Without recurring revenue, Clarity remains dependent on capital resources and successful development progress to support future value creation.

Accelerating Cash BurnPersistent and accelerating operating and free-cash-flow deficits show that losses are translating into substantial cash outflows. Continued burn can increase reliance on external funding, create dilution risk, and constrain the pace or breadth of clinical development if capital access becomes less favorable.

Widening Losses And Negative ReturnsWidening operating and net losses, combined with consistently negative returns on equity, indicate that invested capital is not yet producing economic returns. This weak profitability profile limits internal reinvestment capacity and leaves future earnings dependent on successful product development and commercialization.

Clarity Pharmaceuticals Ltd. News

Clarity Pharmaceuticals Sets Date and Details for 2026 AGM

The latest announcement is out from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ). Clarity Pharmaceuticals has issued a Notice...

2h ago

CU6

State Street Units Exit Substantial Holder Position in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an announcement. State Street Corporation and several of its global...

3d ago

CU6

Clarity Hits SECuRE Recruitment Milestone as Prostate Cancer Theranostic Data Build

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has shared an announcement. Clarity Pharmaceuticals has reached the recruitment target for...

15d ago

CU6

Clarity Pharmaceuticals Updates Corporate Governance Framework for 2026

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an announcement. Clarity Pharmaceuticals has released an updated Corporate Governance...

23d ago

CU6

Clarity Pharmaceuticals Lodges ASX Governance Appendix 4G for FY2026

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an announcement. Clarity Pharmaceuticals has lodged its Appendix 4G with...

23d ago

CU6

Clarity Pharmaceuticals Details Strategy and Progress in 2026 Annual Report

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an announcement. Clarity Pharmaceuticals has released its 2026 annual report,...

23d ago

CU6

State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an update. State Street Corporation, through a group of global...

29d ago

CU6

Clarity Pharmaceuticals Sets AGM Date as It Advances Cancer-Focused Radiopharmaceutical Strategy

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an announcement. Clarity Pharmaceuticals Ltd., listed on the ASX under...

1M ago

CU6

Clarity Pharmaceuticals Lifts Revenue but Posts Wider Loss in FY26 Preliminary Results

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an update. Clarity Pharmaceuticals has released its Appendix 4E preliminary...

2M ago

CU6

State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. State Street Corporation and several of its global...

2M ago

CU6

CU6 FAQ

What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?

Clarity Pharmaceuticals Ltd. lowest share price was AU$1.69 and its highest was AU$5.14 in the past 12 months.

What is Clarity Pharmaceuticals Ltd.’s market cap?

Clarity Pharmaceuticals Ltd.’s market cap is AU$660.35M.

When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?

Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 132 days.

How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?

Clarity Pharmaceuticals Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.125 earnings per share for the quarter, beating the consensus estimate of -AU$0.152 by AU$0.027.

Is Clarity Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clarity Pharmaceuticals Ltd. pay dividends?

Clarity Pharmaceuticals Ltd. does not currently pay dividends.

What is Clarity Pharmaceuticals Ltd.’s EPS estimate?

Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.14.

How many shares outstanding does Clarity Pharmaceuticals Ltd. have?

Clarity Pharmaceuticals Ltd. has 373,081,240 shares outstanding.

What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?

Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.125 in its last earnings report, beating expectations of -AU$0.152. Following the earnings report the stock price went down -6.4%.

Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:CU6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clarity Pharmaceuticals Ltd. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-51.15%

Trailing 12-Months

Asset Growth

96.76%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd. (CU6) Earnings & Revenues

Historic Earnings Reports

CU6 Stock 12 Month Forecast

Average Price Target

AU$6.79

▲(171.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"AU$1","3":"AU$3","5":"AU$5","7":"AU$7","9":"AU$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$8.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.793333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$6.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$5.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.5830769230769235,3.0661538461538465,3.5492307692307694,4.032307692307693,4.515384615384615,4.998461538461539,5.481538461538463,5.964615384615385,6.447692307692309,6.930769230769231,7.413846153846155,7.896923076923079,{"y":8.38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.4610256410256413,2.822051282051282,3.183076923076923,3.5441025641025643,3.9051282051282055,4.266153846153847,4.627179487179488,4.988205128205129,5.34923076923077,5.710256410256411,6.071282051282052,6.432307692307692,{"y":6.793333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.3692307692307693,2.6384615384615384,2.907692307692308,3.176923076923077,3.4461538461538463,3.7153846153846155,3.9846153846153847,4.253846153846154,4.523076923076923,4.792307692307692,5.061538461538461,5.330769230769231,{"y":5.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >